Prosecution Insights
Last updated: September 17, 2026
Application No. 18/856,015

FREE-STATE PLX5622 CRYSTAL FORM AND PREPARATION METHOD THEREFOR

Non-Final OA §112
Filed
Oct 10, 2024
Priority
Apr 15, 2022 — CN 202210400114.X +1 more
Examiner
SZNAIDMAN, MARCOS L
Art Unit
Tech Center
Assignee
Shanghai Haoyuan Medchemexpress Co. Ltd.
OA Round
1 (Non-Final)
37%
Grant Probability
At Risk
1-2
OA Rounds
1y 7m
Est. Remaining
54%
With Interview

Examiner Intelligence

Grants only 37% of cases
37%
Career Allowance Rate
475 granted / 1272 resolved
-22.7% vs TC avg
Strong +16% interview lift
Without
With
+16.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
75 currently pending
Career history
1341
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
38.4%
-1.6% vs TC avg
§102
17.8%
-22.2% vs TC avg
§112
27.8%
-12.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1272 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This office action is in response to applicant’s filing dated October 10, 2024. Status of Claims Claims 1, 3-10 and 12-19 are currently pending and are the subject of this office action. Claims 1, 3-10 and 12-19 are presently under examination. Priority The present application is a 371 of PCT/CN2023/088431 filed on 04/14/2023 and claims priority to foreign application CHINA 202210400114.X filed on 04/15/2022. Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e). Failure to provide a certified translation may result in no benefit being accorded for the non-English application. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 6 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 6 recites: “wherein the crystal form A of compound of formula I has no solvent, and the solvent comprising water” and “wherein the crystal form B of compound of formula I has no solvent, and the solvent comprising water”. However, if the above crystalline forms do not have solvent, why mention that the solvent comprises water. Either it does not comprise a solvent or it comprises water. Allowable Subject Matter Claims 1, 3-5, 7-10 and 12-19 are allowed as presently advised. Conclusion Claim 6 is rejected. Claims 1, 3-5, 7-10 and 12-19 are allowed. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCOS L SZNAIDMAN whose telephone number is (571)270-3498. The examiner can normally be reached Flexing M-F 7 AM-7 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached on 571 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARCOS L SZNAIDMAN/ Primary Examiner, Art Unit 1628 August 13, 2026.
Read full office action

Prosecution Timeline

Oct 10, 2024
Application Filed
Sep 10, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734146
Cobalt-Porphyrin Complexes for the Inactivation of the Biological Activity of Opioids
4y 6m to grant Granted Sep 15, 2026
Patent 12714696
LOW DOSE FLURALANER COMPOSITIONS FOR PROTECTION AGAINST PARASITIC INVERTEBRATE PEST
4y 10m to grant Granted Aug 25, 2026
Patent 12697389
USE OF DIKETONE COMPOUND IN PHOTODYNAMIC THERAPY OR DIAGNOSIS
4y 8m to grant Granted Aug 04, 2026
Patent 12692234
ROCK INHIBITORS AND USES THEREOF
1y 1m to grant Granted Jul 28, 2026
Patent 12685725
PRIDOPIDINE FOR THE TREATMENT OF MITOCHONDRIAL-ASSOCIATED DISEASES AND DISORDERS AND ENDOPLASMIC RETICULUM (ER) STRESS
5y 4m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
37%
Grant Probability
54%
With Interview (+16.2%)
3y 6m (~1y 7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1272 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month